# Safety & Efficacy of Eyecyte-RPE™ in Patients With Geographic Atrophy Secondary to Dry Age-related Macular Degeneration.

> **NCT06394232** · PHASE1,PHASE2 · RECRUITING · sponsor: **Eyestem Research Pvt. Ltd.** · enrollment: 54 (estimated)

## Conditions studied

- Retinal Disease
- Macular Degeneration
- Age-Related Macular Degeneration
- Geographic Atrophy
- Eye Diseases

## Interventions

- **DRUG:** Eyecyte-RPE™

## Key facts

- **NCT ID:** NCT06394232
- **Lead sponsor:** Eyestem Research Pvt. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-06-04
- **Primary completion:** 2025-04
- **Final completion:** 2030-12
- **Target enrollment:** 54 (ESTIMATED)
- **Last updated:** 2024-09-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06394232

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06394232, "Safety & Efficacy of Eyecyte-RPE™ in Patients With Geographic Atrophy Secondary to Dry Age-related Macular Degeneration.". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06394232. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*